CompletedPhase 4

Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Sweden110 participantsStarted 2018-10-18

Plain-language summary

Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * BRVO naïve patients, disease duration 1-6 months, BCVA 23-73 ETDRS letters (20/40-20/320), macula edema with intraretinal cysts and CRT \> 300 micrometers (Cirrus) Exclusion Criteria: * BRVO with neovascular component, intraocular surgery during the previous 3 months, earlier vitreoretinal surgery, vascular retinopathy of other cause, intraocular infection/inflammation, myocardial infarction och cerebrovascular stroke during the last 3 months.

What they're measuring

Difference in time to recurrence of macular edema

Timeframe: 9 months

Trial details

NCT IDNCT03709745

SponsorSt. Erik Eye Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-15

View on ClinicalTrials.gov More Branch Retinal Vein Occlusion with Macular Edema trials